Skip to content

SOCIAL NEUROSCIENCE
GUIDED THERAPEUTICS

SOCIAL NEUROSCIENCE
GUIDED THERAPEUTICS

Developing novel therapeutics for social dysfunction and substance use disorders

Welcome to Kinoxis Therapeutics

Harnessing the power of the social brain to develop novel treatments for social dysfunction and substance use disorders

Social dysfunction is one of the most pervasive and debilitating symptoms across a wide range developmental, psychiatric, and neurological disorders and diseases.
Moreover, social dysfunction has been identified as a major barrier to recovery or improved quality of life for people suffering from many of these conditions.
At Kinoxis Therapeutics, we are developing compounds that help restore normal social functioning by rebalancing activity in malfunctioning social pathways in the brain.
We believe this highly novel approach has the potential to provide treatment breakthroughs for many disorders of the brain and mind.

Who are we?

Kinoxis Therapeutics Pty Ltd (Kinoxis) is a private, Australian-based, late preclinical stage biotechnology company developing first-in-class therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric disorders.

Our Research

The Kinoxis research team is discovering and developing a pipeline of therapeutic compounds that specifically enhance social functioning by targeting pathways in the brain involved in social behavior, with a major focus on the oxytocin receptor.

Kinoxis’ development candidates are novel, small molecules that were discovered through a comprehensive medicinal chemistry and screening program at the University of Sydney.

Our Pipeline

Kinoxis’ lead candidate (KNX100) is being developed for the mitigation of opioid withdrawal symptoms and treatment of agitation and aggression in neurodegenerative and neurodevelopmental disorders. KNX100 has a novel, undisclosed mechanism of action and is nearing Phase I clinical trials.  Kinoxis’ second program is developing compounds that target the oxytocin receptor, through either selective partial agonism or positive allosteric modulation.